Hansson L
Department of Medicine, University of Göteborg, Ostra Hospital, Sweden.
J Hypertens Suppl. 1993 Jun;11(4):S25-7.
Recent clinical trials in the elderly: The results of three major intervention trials against hypertension in the elderly were published in 1991 and 1992. The studies were the Systolic Hypertension in the Elderly Program (SHEP) from the United States, the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) from Sweden and the Medical Research Council (MRC) trial in older adults. In the SHEP trial the recruitment criteria were based on isolated systolic hypertension, whereas the STOP-Hypertension trial and the MRC trial recruited patients with both systolic and diastolic hypertension. In all three trials diuretics and/or beta-blockers (frequently used in combination) formed the basis of active treatment, the patients being randomly allocated either to active treatment or to a placebo. Therapeutic results: The main results for all three trials showed clear benefits from actively lowering elevated arterial pressure in patients aged 60 years or over. In particular, fatal and non-fatal strokes were significantly reduced. In the SHEP trial fatal and non-fatal myocardial infarction and coronary disease were also reduced, and in the STOP trial total mortality was markedly reduced.
三项针对老年人高血压的主要干预试验结果于1991年和1992年公布。这些研究分别是美国的老年收缩期高血压计划（SHEP）、瑞典的老年高血压患者试验（STOP - Hypertension）以及医学研究委员会（MRC）针对老年人的试验。在SHEP试验中，招募标准基于单纯收缩期高血压，而STOP - Hypertension试验和MRC试验招募的是收缩期和舒张期高血压患者。在所有三项试验中，利尿剂和/或β受体阻滞剂（常联合使用）构成了积极治疗的基础，患者被随机分配至积极治疗组或安慰剂组。治疗结果：所有三项试验的主要结果表明，积极降低60岁及以上患者的动脉血压升高有明显益处。特别是，致命和非致命性中风显著减少。在SHEP试验中，致命和非致命性心肌梗死及冠心病也有所减少，在STOP试验中，总死亡率显著降低。
